These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21218391)

  • 21. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
    Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
    Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
    Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
    Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-VEGF Therapy Immediately after Plaque Radiation Therapy Prevents or Delays Radiation Maculopathy.
    Powell BE; Finger PT
    Ophthalmol Retina; 2020 May; 4(5):547-550. PubMed ID: 32192938
    [No Abstract]   [Full Text] [Related]  

  • 24. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin).
    Finger PT
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):974-7. PubMed ID: 18313522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections.
    Nuti E; Traversi C; Marigliani D; Balestrazzi A; Alegente M; Martone G; Malandrini A; Romeo N; Mazzotta C; Tosi GM
    Retina; 2011 Oct; 31(9):1863-70. PubMed ID: 21799465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
    Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
    Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
    Barone A; Russo V; Prascina F; Delle Noci N
    Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
    Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ozurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumab.
    Tarmann L; Langmann G; Mayer C; Weger M; Haas A; Wackernagel W
    Acta Ophthalmol; 2014 Dec; 92(8):e694-6. PubMed ID: 24739457
    [No Abstract]   [Full Text] [Related]  

  • 36. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema.
    Rahimy E; Sarraf D
    Arch Ophthalmol; 2012 Jul; 130(7):931-2. PubMed ID: 22776935
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy.
    Finger PT
    Am J Ophthalmol; 2007 Feb; 143(2):335-8. PubMed ID: 17258524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.